Reported net loss attributable to Valero stockholders of $1.9 billion, or $4.54 per share.Reported adjusted net income attributable to Valero stockholders of […]
First Quarter Financial Highlights*Record revenues of $169.0 million, up 36%Record operating income of $91.1 million, up 44%Operating margin of 53.9%, […]
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) — BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies […]